Skip to Content

ECCO 2019: Vedolizumab and anti-TNF in Crohn’s disease are equally effective

In this MEDtalk Brian Bressler present data from a multi-country, retrospective chart review study assessed the effectiveness and safety of vedolizumab compared with anti-tumour necrosis factors  agents in a real-world cohort of biologic-naïve Crohn’s disease patients.

Få adgang til artiklen

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top